maintaining remission in aml and improving long-term survival in patients who do not receive hsct
Published 3 months ago • 99 plays • Length 2:19Download video MP4
Download video MP3
Similar videos
-
2:15
extending remission in patients with aml who become eligible for allosct following targeted therapy
-
3:47
why maintenance therapy in aml is unnecessary
-
1:44
improving maintenance therapy in aml: exploring the role of idh inhibitors
-
2:03
maintenance therapy in aml
-
2:49
maintenance therapy in aml: agents under investigation and future outlooks
-
1:01
advancements in cml: improving treatment-free remission and novel agents
-
3:26
prolonging remission in aml
-
1:18
an insight into the challenges in prolonging remission in aml
-
3:47
the role of immunotherapy in the aml treatment landscape
-
1:42
novel treatment combinations in aml: what’s to come?
-
0:56
overcoming the challenges in prolonging remission in aml
-
5:31
how does maintenance therapy benefit patients with aml? #aml
-
2:38
emerging strategies for the management of relapsed aml
-
3:57
the role of post-transplant maintenance therapy in aml
-
1:58
maintenance therapy strategies to reduce relapse in aml
-
5:34
updates on maintenance therapies in aml
-
5:11
the frontline treatment strategy for newly diagnosed aml
-
3:40
how the aml treatment landscape has evolved with the use of novel combination therapies
-
1:46
optimizing conditioning regimens in patients with aml undergoing allosct
-
4:15
tom de young | acute myeloid leukaemia (aml) | spot leukaemia
-
6:13
how has acute myeloid leukemia treatment for elderly people changed in 2021?
-
7:46
updates in aml treatment and research from asco 2023